Belite Bio (Belite Bio) Cash-to-Debt : N/A (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Belite Bio's cash to debt ratio for the quarter that ended in Mar. 2024 was N/A.

The historical rank and industry rank for Belite Bio's Cash-to-Debt or its related term are showing as below:

During the past 4 years, Belite Bio's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 5049.75.

BLTE's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.89
* Ranked among companies with meaningful Cash-to-Debt only.

Belite Bio Cash-to-Debt Historical Data

The historical data trend for Belite Bio's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Belite Bio Cash-to-Debt Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

48.60

99.50

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial							N/A	N/A	N/A	99.50	N/A

Competitive Comparison of Belite Bio's Cash-to-Debt

For the Biotechnology subindustry, Belite Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belite Bio's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Belite Bio's Cash-to-Debt falls into.

Belite Bio Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Belite Bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	88.157	/	(0.308	+	0.578)
	=	99.50

Belite Bio's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Belite Bio (NAS:BLTE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Belite Bio Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Belite Bio's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.